Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2017
SIETES contiene 92082 citas

 
 
 1 a 20 de 272 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250-9. [Ref.ID 102073]
2. Cita con resumen
Sugiyama T. Osteoporotic fractures associated with dabigatran vs warfarin. JAMA 2017;318:90-1. [Ref.ID 102054]
3.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
4. Cita con resumen
Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol 2017;83:642-52. [Ref.ID 101934]
5.Enlace a cita original Cita con resumen
Lau WCY, Chan EW, Cheung C-L, Sing CW, Man KK, Lip GY, Siu CW, Lam JK, Lee AC, Wong IC. Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA 2017;317:1151-8. [Ref.ID 101498]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Stolk LM, de Vries F, Ebbelaar C, de Boer A, Schalekamp T, Souverein P, ten Cate-Hoek A, Burden AM. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101480]
8.Enlace a cita original Cita con resumen
Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, Vaccheri A, Motola D. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2017;83:1532-43. [Ref.ID 101351]
9. Cita con resumen
Nielen JTH, Dagnelie PC, Emans PJ, Veldhorst-Janssen N, Lalmohamed A, Van Staa T-P, Boonen AERCH, van den Bemt BJF, de Vries F. Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements. Pharmacoepidemiol Drug Saf 2016;25:1245-52. [Ref.ID 100896]
10.Enlace a cita original Cita con resumen
Mahtani KR, Heneghan C. Novel oral anticoagulants for atrial fibrillation. BMJ 2016;354:i5187. [Ref.ID 100782]
11. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Hsueh Y-H, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016:3 de octubre. [Ref.ID 100779]
12.Enlace a cita original
Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. Br J Clin Pharmacol 2016;82:633-44. [Ref.ID 100732]
13. Cita con resumen
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189. [Ref.ID 100605]
14. Cita con resumen
15. Cita con resumen
Anónimo. Idarucizumab. Prescrire 2016;36:494-9. [Ref.ID 100551]
16. Cita con resumen
Gómez-Outes A, Lecumberri R. Antídotos de los nuevos anticoagulantes orales: realidad y expectativas. Med Clin (Barc) 2016;146:488-90. [Ref.ID 100372]
17.Enlace a cita original Cita con resumen
Erviti López J. Incertidumbres sobre los nuevos anticoagulantes orales en fibrilación auricular Irregularidades y lagunas en su autorización. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-12. [Ref.ID 100353]
18. Cita con resumen
Kuehn BM. FDA's foray into big data still maturing. JAMA 2016;315:1934-6. [Ref.ID 100291]
19.Enlace a cita original Cita con resumen
Barceló ME. Hepatotoxicitat amb tots els anticoagulants d'acció directa. Comptagotes. Butlletí d'actualització terapèutica 2016:1-2. [Ref.ID 100211]
20. Cita con resumen
Anónimo. Which oral anticoagulant for atrial fibrillation?. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:45-6. [Ref.ID 100209]
Seleccionar todas
 
 1 a 20 de 272 siguiente >>